Myelofibrosis and myeloproliferative neoplasms
Clinical research in myelofibrosis includes both JAK inhibitor-naïve and previously treated populations, with attention to moderate thrombocytopenia and treatment-naïve disease. The sponsor also studies combinations involving ruxolitinib in this hematologic setting.
- JAK inhibitor-naïve myelofibrosis
- Previously treated myelofibrosis
- Treatment-naïve myelofibrosis
- Moderate thrombocytopenia
The research focus centers on disease control in chronic marrow-related disorders and symptom burden associated with myelofibrosis.
Multiple myeloma
Trials in multiple myeloma address heavily pretreated disease, including penta-refractory multiple myeloma and triple-class refractory multiple myeloma. The therapeutic interest extends to regimens combining dexamethasone with other anti-myeloma agents.
- Penta-refractory multiple myeloma
- Triple-class refractory multiple myeloma
- Combination therapy in relapsed myeloma
These studies reflect a focus on advanced plasma cell malignancy and treatment-resistant hematologic cancer.
Diffuse large B-cell lymphoma
Research in diffuse large B-cell lymphoma covers relapsed/refractory DLBCL and RR DLBCL, with interest in combining selinexor-based therapy with established rituximab-containing backbones. The sponsor also examines outcomes in patients with persistent disease after prior treatment.
- Relapsed/refractory DLBCL
- Rituximab-based combinations
- Refractory B-cell lymphoma
The lymphoma portfolio is centered on aggressive B-cell malignancies with limited treatment options.
Endometrial cancer
In endometrial cancer, the sponsor studies maintenance treatment for advanced and recurrent disease. This area reflects interest in gynecologic oncology and in prolonging disease control after initial therapy.
- Advanced endometrial cancer
- Recurrent endometrial cancer
- Maintenance therapy
The oncology program extends beyond hematology into solid tumors, with a focus on gynecologic malignancy.
